Details for Patent: 11,542,239
✉ Email this page to a colleague
Which drugs does patent 11,542,239 protect, and when does it expire?
Patent 11,542,239 protects ORIAHNN (COPACKAGED) and ORILISSA and is included in two NDAs.
This patent has nine patent family members in eight countries.
Drugs Protected by US Patent 11,542,239
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | CAPSULE;ORAL | 213388-001 | May 29, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| Abbvie | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-001 | Jul 23, 2018 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| Abbvie | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-002 | Jul 23, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,542,239
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019309706 | ⤷ Subscribe | |||
| Brazil | 112021000973 | ⤷ Subscribe | |||
| Canada | 3104902 | ⤷ Subscribe | |||
| China | 112469417 | ⤷ Subscribe | |||
| European Patent Office | 3826638 | ⤷ Subscribe | |||
| Israel | 280135 | ⤷ Subscribe | |||
| Israel | 310267 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
